Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Aug 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two types of imaging tests—Multi-parametric MRI (mpMRI) and dual-energy CT (DECT)—to see how well they can help doctors determine the stage of gastric cancer before surgery. Knowing the exact stage is crucial because it helps doctors decide the best treatment plan for patients, ensuring they receive the right amount of treatment.

To be eligible for this trial, participants must be adults aged 65 to 74 who have been diagnosed with gastric cancer through endoscopy and have not received any previous treatment for this condition. They also need to be able to safely undergo the imaging tests without any severe allergies to the contrast agents used in these scans. Patients who have had recurrent gastric cancer or have certain imaging issues that could affect the results are not eligible. Those who participate can expect to undergo both imaging tests as part of the study, which aims to improve how gastric cancer is diagnosed and treated.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Consecutive patients with preoperative pathologically confirmed GC by endoscopy and preoperative imaging data (DECT/mpMRI) were included.
• • No contraindications for CT/MRI examination
• • Written informed consent
• Exclusion Criteria:
• • Patients with a history of previous therapy.
• • Patients with recurrent gastric cancer
• • Patients with a history of severe allergy to contrast agents
• • Patients with imaging artefacts affect the evaluation